Is It Time to Introduce PET/CT in Colon Cancer Guidelines?

Abstract

International colon cancer guidelines suggest F-FDG PET/CT in a few circumstances: (1) at disease presentation in case of suspected or proven metastatic synchronous adenocarcinoma; (2) in the workup of recurrent colon cancer with metachronous metastases documented by CT, MRI, or biopsy and in case of serial CEA elevation with negative colonoscopy and negative CT; and (3) in case of contraindication to iodine- and gadolinium-based contrast agents. However, review of the literature has shown that PET/CT can also be used in other scenarios with significant levels of diagnostic advantage. This review aims to emphasize differences between guidelines and scientific literature for the use of PET/CT in colon cancer.

• Authors: Anna Margherita Maffione, Domenico Rubello, Paola Caroli, Patrick M Colletti, Federica Matteucci
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 45 Issue 7 Pg. 525-530 (Jul 2020) ISSN: 1536-0229 [Electronic] United States
• PMID: 32433179 (Publication Type: Journal Article)

Chemical References

• Contrast Media
• Fluorodeoxyglucose F18

Topics

• Adenocarcinoma (diagnostic imaging, pathology)
• Aged
• Biopsy
• Colonic Neoplasms (diagnostic imaging, pathology)
• Contrast Media
• Female
• Fluorodeoxyglucose F18
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Neoplasm Metastasis
• Positron Emission Tomography Computed Tomography
• Practice Guidelines as Topic